Study of Febrile Illness for Dengue-Endemic Areas in Latin America
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to detect acute febrile episodes and dengue infection in five Latin American countries to assess dengue seroprevalence.
Primary objectives:
- To identify acute febrile episodes among the cohort in order to detect the presence of dengue infection.
- To describe the dengue seroprevalence among the cohort at baseline and at the end of the study.
| Condition |
|---|
|
Dengue Fever Fever |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Latin America |
- Identification of acute febrile episodes in the cohort [ Time Frame: Up to 18 months after study entry ] [ Designated as safety issue: No ]
- Detection of confirmed or probable dengue infection in the cohort [ Time Frame: Up to 18 months after study entry ] [ Designated as safety issue: No ]
| Enrollment: | 3000 |
| Study Start Date: | August 2010 |
| Study Completion Date: | April 2012 |
| Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Study Cohort (Case )
Participants will be examined for fever in dengue endemic regions
|
Detailed Description:
All participants will make two visits to a study site, an enrollment visit and a termination visit. Additional visits will be made if febrile episodes occur: an acute visit and a convalescent visit. Participants or their parents/guardians will be contacted weekly to monitor the occurrence of febrile episodes and ensure appropriate assessment and care.
No vaccine will be provided or administered in this study
Eligibility| Ages Eligible for Study: | 9 Years to 16 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Participants aged 9 to 16 years in 4 countries in Latin America: Brazil, Mexico, Colombia and Puerto Rico
Inclusion Criteria :
- Aged 9 to 16 years on the day of inclusion and resident of the site zone
- Participant in good health, based on medical history and physical examination
- Assent form has been signed and dated by the participant (if required by local regulations), and informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (and by the participant and/or an independent witness if required by local regulations)
- Participant able to attend all scheduled visits and to comply with all study procedures
Exclusion Criteria :
- Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding enrollment
- Planned participation in another clinical trial during the present study period
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Self-reported seropositivity for Human Immunodeficiency Virus (HIV) infection
- Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
- Current alcohol abuse or drug addiction that may interfere with the participant's ability to comply with study procedures
- Receipt of blood or blood-derived products in the past 3 months
- Receipt of any vaccine in the 4 weeks preceding the day of enrollment except for pandemic influenza vaccination, which may be received at least 2 weeks before enrollment
- Planned receipt of any vaccine in the 4 weeks following enrollment
- Deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily
- Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.
Contacts and Locations| Brazil | |
| Campo Grande, Brazil, 79074460 | |
| Goiania, Brazil, 74675-020 | |
| Natal-RN, Brazil, 59025-600 | |
| Vitoria, Brazil, 29040-091 | |
| Colombia | |
| Acacias Meta, Colombia | |
| Aguazul (Casanare), Colombia | |
| Bogota, Colombia | |
| Calarco (Quindio), Colombia | |
| Girardot (Cundinamarca), Colombia | |
| La Tebaida (Quindio), Colombia | |
| Montenegro (Quindio), Colombia | |
| Yopal (Casanare), Colombia | |
| Mexico | |
| Minatitlan, Veracruz Mexico, Mexico, 96760 | |
| Veracruz, Veracruz Mexico, Mexico, 91900 | |
| Municipio de Cd. Mante Tamaulipas, Mexico | |
| Quintana Roo., Mexico | |
| Puerto Rico | |
| Guayama, Puerto Rico, 00784 | |
| San Juan, Puerto Rico, 00918 | |
| Study Director: | Regional Director | Sanofi Pasteur SA. |
More Information
Additional Information:
No publications provided
| Responsible Party: | Sanofi |
| ClinicalTrials.gov Identifier: | NCT01293331 History of Changes |
| Other Study ID Numbers: | CYD35, U1111-1112-8481 |
| Study First Received: | February 9, 2011 |
| Last Updated: | August 2, 2012 |
| Health Authority: | United States: Food and Drug Administration Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos Mexico: Ministry of Health Brazil: Ministry of Health |
Keywords provided by Sanofi:
|
Dengue Fever Fever Seroprevalence |
Additional relevant MeSH terms:
|
Dengue Dengue Hemorrhagic Fever Fever Arbovirus Infections Virus Diseases Flavivirus Infections |
Flaviviridae Infections RNA Virus Infections Hemorrhagic Fevers, Viral Body Temperature Changes Signs and Symptoms |
ClinicalTrials.gov processed this record on May 19, 2013